Mar
07
2025
March 7, 2025
ISN Webinar: Understanding the cardiovascular effects of GLP-1 Receptor Agonists and implications in patients with CKD and cardiovascular disease
- 3 PM CET
This webinar is only available for healthcare professionals
This webinar aims to review the various cardiovascular outcome trials of GLP-1 receptor agonists (GLP-1RAs) conducted in patients with cardiovascular risk with or without diabetes and relevance of these findings in managing patients with chronic kidney disease (CKD), diabetes and cardiovascular disease. The session will delve into practical guidance for integrating GLP-1RAs into existing therapeutic strategies for cardiovascular protection in diabetes and CKD.
Learning objectives:
- Review the various cardiovascular outcome trials of GLP-1 receptor agonists (GLP-1RAs) to date and discuss if there is any difference in the efficacy and risk between the different GLP-1RAs tested.
- Review the pleotropic mechanisms of cardiovascular protective effects of GLP1-RA.
- Provide practical guidance on combination therapies: how to incorporate GLP-1RAs into the current foundation therapies for cardiovascular protection in Type 2 diabetes and CKD.
Further reading:
- ISN Webinar: Unraveling the biology of GLP1-receptor agonist for obesity management and metabolic control in CKD
- ISN Webinar: How GLP1 receptor agonist evolved from weight management drugs to kidney protective therapy?
This webinar is supported by Novo Nordisk.
Moderators
Angela Yee-Moon Wang (Singapore)
Speakers
Adeera Levin (Canada)
Nikolaus Marx (Germany)